# Brigitte Smith

> Brigitte Smith is a Series D investor at GBS Ventures backing Health Care and Biotechnology. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [GBS Ventures](https://shizune.co/investors/profile/gbs-ventures)
- Location: Melbourne, Australia
- Total investments: 14
- Last investment: Aug 2024
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://au.linkedin.com/in/brigitte-smith-0170226

Brigitte Smith is a Series D investor at GBS Ventures in Melbourne focused on Health Care and Biotechnology. Brigitte Smith is the Co-Founder and Managing Partner at GBS since 1996. Brigitte has twenty years’ experience in venture capital, business strategy and start-up company operations. Brigitte has been investing and managing investments for GBS’s $450m of life science specialised venture capital funds since 1998. Brigitte is on the board of GBSportfolio companies AirXpanders Inc, Endoluminal Sciences Pty Ltd, Neuromonics Pty Ltd, Proacta Inc, and Vivive Inc. Brigitte was the founding Investor and Chair of Pharmaxis Pty Ltd. Prior to founding GBS Brigitte worked in the US and Australia in operating roles with early stage technology based companies and at Bain & Company as a Strategic Management Consultant. Brigitte has a B.Chem Eng (Honours) from the University of Melbourne and as a Fulbright Scholar completed a MBA (Honours) from the Harvard Business School and a MALD from the Fletcher School of Law and Diplomacy, both in Boston, USA.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 21% |
| Biotechnology | 3 | 21% |
| Medical Device | 2 | 14% |
| Biopharma | 1 | 7% |
| Pharmaceutical | 1 | 7% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 3 | 21% |
| Series B | 2 | 14% |
| Series C | 2 | 14% |
| Series E | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $61M | Series D | Aug 13, 2024 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $40M | Series C | Aug 16, 2022 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $50M | Series C | Mar 17, 2017 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $12.6M | Series B | Jan 27, 2016 |  |
| Moximed | Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $33M | Series B | May 07, 2015 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $1M | Series E | Sep 03, 2014 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $9M | Series E | Jun 03, 2013 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $11M | Series D | Apr 20, 2012 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $10.3M | Series D | Jan 23, 2012 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $3M | Series C | Mar 02, 2011 |  |

10 of 14 investments shown.

## Co-investors
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 5 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 4 deals together
- [Prolog Ventures](https://shizune.co/investors/profile/prolog-ventures) — VC Fund, 4 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 3 deals together
- [Future Fund](https://shizune.co/investors/profile/future-fund) — VC Fund, 3 deals together

## About GBS Ventures

VC Fund · Melbourne, Australia

Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.

4 contacts available at GBS Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Ben Gust | Partner | https://shizune.co/investors/profile/ben-gust |
| Brigitte Smith | Co-Founder & Managing Partner | https://shizune.co/investors/profile/brigitte-smith |
| George Morstyn | Investment Committee Member | https://shizune.co/investors/profile/george-morstyn |
| John Mills | Investment Committee Member | https://shizune.co/investors/profile/john-mills-3 |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Brigitte Smith invest in?

Brigitte Smith invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series D and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Brigitte Smith last invest?

The most recent investment recorded for Brigitte Smith closed in Aug 2024. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co